Literature DB >> 26550538

Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma.

Christos Sachpekidis1, Jens Hillengass2, Hartmut Goldschmidt2, Jennifer Mosebach3, Leyun Pan1, Heinz-Peter Schlemmer3, Uwe Haberkorn4, Antonia Dimitrakopoulou-Strauss1.   

Abstract

PET/MRI represents a promising hybrid imaging modality with several potential clinical applications. Although PET/MRI seems highly attractive in the diagnostic approach of multiple myeloma (MM), its role has not yet been evaluated. The aims of this prospective study are to evaluate the feasibility of (18)F-FDG PET/MRI in detection of MM lesions, and to investigate the reproducibility of bone marrow lesions detection and quantitative data of (18)F-FDG uptake between the functional (PET) component of PET/CT and PET/MRI in MM patients. The study includes 30 MM patients. All patients initially underwent (18)F-FDG PET/CT (60 min p.i.), followed by PET/MRI (120 min p.i.). PET/CT and PET/MRI data were assessed and compared based on qualitative (lesion detection) and quantitative (SUV) evaluation. The hybrid PET/MRI system provided good image quality in all cases without artefacts. PET/MRI identified 65 of the 69 lesions, which were detectable with PET/CT (94.2%). Quantitative PET evaluations showed the following mean values in MM lesions: SUVaverage=5.5 and SUVmax=7.9 for PET/CT; SUVaverage=3.9 and SUVmax=5.8 for PET/MRI. Both SUVaverage and SUVmax were significantly higher on PET/CT than on PET/MRI. Spearman correlation analysis demonstrated a strong correlation between both lesional SUVaverage (r=0.744) and lesional SUVmax (r=0.855) values derived from PET/CT and PET/MRI. Regarding detection of myeloma skeletal lesions, PET/MRI exhibited equivalent performance to PET/CT. In terms of tracer uptake quantitation, a significant correlation between the two techniques was demonstrated, despite the statistically significant differences in lesional SUVs between PET/CT and PET/MRI.

Entities:  

Keywords:  Multiple myeloma; PET/CT; PET/MRI; SUV

Year:  2015        PMID: 26550538      PMCID: PMC4620174     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  31 in total

1.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

Review 2.  Clinical and research applications of simultaneous positron emission tomography and MRI.

Authors:  F Fraioli; S Punwani
Journal:  Br J Radiol       Date:  2013-11-14       Impact factor: 3.039

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

4.  Whole-body (18)F-FDG PET identifies high-risk myeloma.

Authors:  Brian G M Durie; Alan D Waxman; Allesandro D'Agnolo; Cindy M Williams
Journal:  J Nucl Med       Date:  2002-11       Impact factor: 10.057

Review 5.  The role of imaging techniques in the management of multiple myeloma.

Authors:  Elena Zamagni; Michele Cavo
Journal:  Br J Haematol       Date:  2012-08-11       Impact factor: 6.998

6.  Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner.

Authors:  Gaspar Delso; Sebastian Fürst; Björn Jakoby; Ralf Ladebeck; Carl Ganter; Stephan G Nekolla; Markus Schwaiger; Sibylle I Ziegler
Journal:  J Nucl Med       Date:  2011-11-11       Impact factor: 10.057

7.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Authors:  Meletios Dimopoulos; Robert Kyle; Jean-Paul Fermand; S Vincent Rajkumar; Jesus San Miguel; Asher Chanan-Khan; Heinz Ludwig; Douglas Joshua; Jayesh Mehta; Morie Gertz; Hervé Avet-Loiseau; Meral Beksaç; Kenneth C Anderson; Philippe Moreau; Seema Singhal; Hartmut Goldschmidt; Mario Boccadoro; Shaji Kumar; Sergio Giralt; Nikhil C Munshi; Sundar Jagannath
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

8.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

Authors:  Twyla B Bartel; Jeff Haessler; Tracy L Y Brown; John D Shaughnessy; Frits van Rhee; Elias Anaissie; Terri Alpe; Edgardo Angtuaco; Ronald Walker; Joshua Epstein; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

9.  Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET.

Authors:  Antonia Dimitrakopoulou-Strauss; Martin Hoffmann; Raoul Bergner; Michael Uppenkamp; Uwe Haberkorn; Ludwig G Strauss
Journal:  Clin Nucl Med       Date:  2009-09       Impact factor: 7.794

10.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

View more
  14 in total

Review 1.  The Critical Role of Imaging in the Management of Multiple Myeloma.

Authors:  Shahzad Raza; Siyang Leng; Suzanne Lentzsch
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

2.  Diagnostic performance of 18F-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study.

Authors:  Mohammad Abd Alkhalik Basha; Maged Abdel Gelil Hamed; Rania Refaat; Mohamad Zakarya AlAzzazy; Manar A Bessar; Elshaimaa Mohamed Mohamed; Ayman F Ahmed; Heba Fathy Tantawy; Khaled Mohamed Altaher; Ahmed Ali Obaya; Amira Hamed Mohamed Afifi
Journal:  Jpn J Radiol       Date:  2018-04-18       Impact factor: 2.374

Review 3.  Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.

Authors:  David Dingli; Sikander Ailawadhi; P Leif Bergsagel; Francis K Buadi; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Wilson I Gonsalves; Susan R Hayman; Prashant Kapoor; Taxiarchis Kourelis; Shaji K Kumar; Robert A Kyle; Martha Q Lacy; Nelson Leung; Yi Lin; John A Lust; Joseph R Mikhael; Craig B Reeder; Vivek Roy; Stephen J Russell; Taimur Sher; A Keith Stewart; Rahma Warsame; Stephen R Zeldenrust; S Vincent Rajkumar; Asher A Chanan Khan
Journal:  Mayo Clin Proc       Date:  2017-03-11       Impact factor: 7.616

Review 4.  PET/MRI: Where might it replace PET/CT?

Authors:  Eric C Ehman; Geoffrey B Johnson; Javier E Villanueva-Meyer; Soonmee Cha; Andrew Palmera Leynes; Peder Eric Zufall Larson; Thomas A Hope
Journal:  J Magn Reson Imaging       Date:  2017-03-30       Impact factor: 4.813

Review 5.  Imaging in myeloma with focus on advanced imaging techniques.

Authors:  Tara Barwick; Laure Bretsztajn; Kathryn Wallitt; Dimitri Amiras; Andrea Rockall; Christina Messiou
Journal:  Br J Radiol       Date:  2019-01-03       Impact factor: 3.039

6.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

7.  Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities.

Authors:  Christos Sachpekidis; Jennifer Mosebach; Martin T Freitag; Thomas Wilhelm; Elias K Mai; Hartmut Goldschmidt; Uwe Haberkorn; Heinz-Peter Schlemmer; Stefan Delorme; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

8.  Quantitative comparison of PET performance-Siemens Biograph mCT and mMR.

Authors:  Anna M Karlberg; Oddbjørn Sæther; Live Eikenes; Pål Erik Goa
Journal:  EJNMMI Phys       Date:  2016-02-25

Review 9.  Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.

Authors:  Esther G M de Waal; Andor W J M Glaudemans; Carolien P Schröder; Edo Vellenga; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-29       Impact factor: 9.236

10.  Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to 18F-FDG PET/CT.

Authors:  Dong Zheng; Yi Liu; Jiajin Liu; Ke Li; Mu Lin; Holger Schmidt; Baixuan Xu; Jiahe Tian
Journal:  Cancer Imaging       Date:  2020-06-16       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.